Literature DB >> 21070513

Costs and outcomes of VCT delivery models in the context of scaling up services in Indonesia.

Adiatma Y M Siregar1, Dindin Komarudin, Rudi Wisaksana, Reinout van Crevel, Rob Baltussen.   

Abstract

OBJECTIVE: To evaluate costs and outcomes of voluntary counselling and testing (VCT) service delivery models in urban Indonesia.
METHODS: We collected primary data on utilization, costs and outcomes of VCT services in a hospital clinic (568 clients), HIV community clinic (28 clients), sexually transmitted infection (STI) community clinic (784 clients) and prison clinic (574 clients) in Bandung, Indonesia, in the period January 2008-April 2009.
RESULTS: The hospital clinic diagnosed the highest proportion and absolute number of HIV infections, but with the lowest average CD4 cell count and with the highest associated travelling and waiting time. The prison clinic detected fewer cases, but at an earlier stage, and all enrolled in HIV care. The community clinics detected the smallest number of cases, and only 0-8% enrolled in HIV care. The unit cost per VCT was highest in the hospital clinic (US$74), followed by the STI community clinic (US$65), the HIV community clinic (US$39) and the prison (US$23).
CONCLUSION: We propose a reorientation of the delivery models for VCT and related HIV/AIDS treatment in this setting. We call for the scaling up of community clinics for VCT to improve access, promote earlier detection and to perform (early) treatment activities. This would reduce the burden of the hospital clinic to orient itself towards the treatment of AIDS patients. This is one of very few studies addressing this issue in Asia and the first of its kind in Indonesia, which has a rapidly growing HIV epidemic. The conceptual framework and overall conclusions may be relevant to other low-income settings.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21070513     DOI: 10.1111/j.1365-3156.2010.02675.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  6 in total

Review 1.  Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries.

Authors:  Mariana Siapka; Michelle Remme; Carol Dayo Obure; Claudia B Maier; Karl L Dehne; Anna Vassall
Journal:  Bull World Health Organ       Date:  2014-04-01       Impact factor: 9.408

2.  Costs of HIV/AIDS treatment in Indonesia by time of treatment and stage of disease.

Authors:  Adiatma Y M Siregar; Noor Tromp; Dindin Komarudin; Rudi Wisaksana; Reinout van Crevel; Andre van der Ven; Rob Baltussen
Journal:  BMC Health Serv Res       Date:  2015-09-30       Impact factor: 2.655

3.  Primary health care and family medicine at the core of health care: challenges and priorities in how to further strengthen their potential.

Authors:  Chris van Weel
Journal:  Front Med (Lausanne)       Date:  2014-10-16

4.  Assessing cost and technical efficiency of HIV prevention interventions in sub-Saharan Africa: the ORPHEA study design and methods.

Authors:  Sergio Bautista-Arredondo; Sandra G Sosa-Rubí; Marjorie Opuni; Ada Kwan; Claire Chaumont; Jenny Coetzee; Jeanine Condo; Kumbutso Dzekedzeke; Omar Galárraga; Neil Martinson; Felix Masiye; Sabin Nsanzimana; Richard Wamai; Joseph Wang'ombe
Journal:  BMC Health Serv Res       Date:  2014-11-29       Impact factor: 2.655

5.  Prioritizing HIV/AIDS prevention strategies in Bandung, Indonesia: A cost analysis of three different HIV/AIDS interventions.

Authors:  Inge de Bresser; Toine E P Remers; Monse W M Wieland; Rozar Prawiranegara; Adiatma Y M Siregar; Rob Baltussen
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

6.  Integrating HIV services and other health services: A systematic review and meta-analysis.

Authors:  Caroline A Bulstra; Jan A C Hontelez; Moritz Otto; Anna Stepanova; Erik Lamontagne; Anna Yakusik; Wafaa M El-Sadr; Tsitsi Apollo; Miriam Rabkin; Rifat Atun; Till Bärnighausen
Journal:  PLoS Med       Date:  2021-11-09       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.